Tag: Metabolic Research

Research on metabolic signaling peptides including Semaglutide, Tirzepatide, Retatrutide, and Cagrilintide.

Posted on by — Leave a comment

Semaglutide Research Overview: GLP-1 Receptor Signaling & Metabolic Biology

For research use only. Semaglutide is not approved by the FDA for use in this research chemical context and is sold by Iron Labs exclusively for laboratory research. Not for human consumption.

Semaglutide in Research Context

Semaglutide is a long-acting GLP-1 receptor agonist that has become one of the most extensively studied synthetic peptides in metabolic biology over the past decade. Its molecular architecture — a 31-amino acid sequence with fatty acid conjugation at lysine-26 — enables albumin binding that produces a half-life of approximately 7 days in human pharmacokinetic studies. For research purposes, Semaglutide’s extended pharmacokinetic profile and well-characterized receptor binding makes it a valuable tool in GLP-1 pathway studies.

GLP-1 Receptor Signaling: What Researchers Study

The GLP-1 receptor (GLP-1R) is a class B G protein-coupled receptor expressed in pancreatic beta cells, the hypothalamus, brainstem, heart, kidney, and several other tissues. Research using GLP-1R agonists like Semaglutide investigates:

  • Pancreatic beta-cell biology: GLP-1R activation stimulates cAMP production in beta cells, potentiating glucose-dependent insulin secretion. Research has examined downstream PKA and EPAC signaling pathways in cell culture and animal models.
  • Central appetite signaling: Hypothalamic and brainstem GLP-1R expression is implicated in satiety signaling. Animal research has examined how GLP-1R agonists influence food intake behavior, neuropeptide Y expression, and arcuate nucleus activity.
  • Cardiovascular research: Semaglutide has been examined in cardiovascular outcome models, with research focusing on cardiac GLP-1R expression, inflammatory cytokine modulation, and endothelial function in preclinical settings.
  • Hepatic lipid metabolism: Animal models have examined Semaglutide’s effects on hepatic steatosis, triglyceride synthesis, and fatty acid oxidation pathways.
  • Kidney biology: GLP-1R is expressed in renal tubular cells; research has examined GLP-1R agonism in models of kidney inflammation and proteinuria.

Semaglutide vs. Tirzepatide in Research

Tirzepatide’s dual GIP/GLP-1 agonism has made direct comparison with single-agonist Semaglutide a major area of metabolic research interest. Studies comparing both compounds in preclinical models have examined receptor occupancy, downstream signaling depth, and adipose tissue response. The addition of GIP receptor agonism in Tirzepatide appears to produce additive or synergistic metabolic effects in animal models, though the precise mechanisms continue to be studied.

Laboratory Handling

Semaglutide is supplied as lyophilized powder. Reconstitute with bacteriostatic water. Store lyophilized stock at -20°C; reconstituted solution at 2–8°C protected from light. Use within 28 days of reconstitution. Semaglutide is sensitive to light degradation due to its fatty acid conjugation.

Source Semaglutide for your research → Iron Labs Research Catalog

Regulatory Notice

Semaglutide sold by Iron Labs is a research chemical for laboratory use only. It is not sold or intended for human therapeutic use. Iron Labs makes no health, weight loss, or metabolic claims. Researchers are responsible for compliance with all applicable regulations in their jurisdiction.

Posted on by — Leave a comment

MOTS-C Research Overview: Mitochondrial Peptide Science & Metabolic Biology

For research use only. MOTS-C is not approved by the FDA for human use and is sold exclusively as a research chemical. Not for human consumption.

What Is MOTS-C?

MOTS-C (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a mitochondrial-derived peptide (MDP) encoded within the 12S ribosomal RNA gene of the mitochondrial genome. It was first identified and characterized in 2015 by researchers at the University of Southern California, making it one of the more recently discovered peptides in metabolic biology research. Unlike most peptides, MOTS-C is mitochondrially encoded rather than nuclear-encoded, placing it in a novel class of signaling molecules with unique research implications.

MOTS-C in Metabolic Research

MOTS-C has generated significant interest in metabolic biology and longevity research since its discovery. Key research areas include:

  • Insulin sensitivity models: The original 2015 paper demonstrated that MOTS-C regulates insulin sensitivity in skeletal muscle cells, with observations on AMPK pathway activation and glucose uptake in in vitro models.
  • Exercise biology: Research has examined MOTS-C as an “exercise mimetic,” with animal studies showing that MOTS-C administration produced metabolic adaptations similar to physical exercise, including increased mitochondrial biogenesis markers.
  • Aging and longevity research: Studies have investigated MOTS-C levels in aging populations and animal models, with observations suggesting that circulating MOTS-C levels decline with age and that supplementation may influence healthspan markers in rodent models.
  • Obesity and adipose tissue biology: Animal research has examined MOTS-C in diet-induced obesity models, with observations on fat accumulation, energy expenditure, and inflammatory cytokine expression in adipose tissue.
  • Nuclear translocation: Notably, research has demonstrated that MOTS-C can translocate from mitochondria to the cell nucleus in response to metabolic stress, where it modulates nuclear gene expression — an unusual mechanism for a mitochondrially-encoded peptide.

MOTS-C vs. Epitalon: Longevity Research Context

Both MOTS-C and Epitalon appear in longevity-focused research literature, but through entirely different mechanisms. MOTS-C research centers on mitochondrial signaling, AMPK activation, and metabolic regulation. Epitalon research focuses on telomerase activity and pineal biology. Researchers studying biological aging often examine both in parallel to address different hallmarks of the aging process.

Laboratory Handling

MOTS-C is supplied as lyophilized powder. Store at -20°C; reconstitute with bacteriostatic water. Reconstituted solution stable at 2–8°C for up to 28 days. Protect from light and repeated freeze-thaw cycles.

Source MOTS-C for your research → Iron Labs Research Catalog

Regulatory Notice

MOTS-C is not FDA-approved for any human or veterinary use. Iron Labs sells MOTS-C exclusively as a research chemical. No health, anti-aging, or metabolic claims are made or implied.

Posted on by — Leave a comment

GLP-1 & Metabolic Peptides: Research Overview of Semaglutide, Tirzepatide & More

For research use only. GLP-1 receptor agonist peptides including Semaglutide and Tirzepatide are discussed here strictly as research compounds. These are not approved by Iron Labs for human use and are sold exclusively for laboratory research.

The Science of GLP-1 Receptor Research

Glucagon-like peptide-1 (GLP-1) is an incretin hormone naturally secreted from intestinal L-cells in response to nutrient intake. Its receptor, GLP-1R, is expressed across multiple tissue types including the pancreas, brain, heart, and kidneys, making it a target of substantial academic and pharmaceutical research interest. The development of synthetic GLP-1 receptor agonist peptides has been one of the most significant areas of metabolic biology research over the past two decades.

Key GLP-1 Peptides Under Research Investigation

Semaglutide

Semaglutide is a long-acting GLP-1 receptor agonist with a half-life of approximately 7 days, achieved through fatty acid conjugation enabling albumin binding. In research models, Semaglutide has been studied extensively in the context of pancreatic beta-cell function, central appetite signaling, and cardiovascular risk biomarkers. Its molecular structure incorporates substitutions at positions 8 and 34 of native GLP-1 to resist DPP-4 degradation.

Tirzepatide

Tirzepatide is a dual GIP/GLP-1 receptor agonist, representing a newer class of metabolic research peptide. Its dual-agonist mechanism has generated substantial research interest due to observed additive effects on insulin secretion pathways and appetite-regulating neuronal circuits in preclinical models. Studies have examined its influence on adipose tissue biology, hepatic lipid metabolism, and energy expenditure signaling.

Cagrilintide

Cagrilintide is a long-acting amylin analogue studied in combination with Semaglutide in clinical research settings. Amylin receptors are expressed in the central nervous system and play a role in satiety signaling research, distinct from GLP-1 pathways but often co-investigated in metabolic biology studies.

Research Applications Overview

CompoundReceptor Target(s)Primary Research AreasHalf-Life
SemaglutideGLP-1RMetabolic signaling, beta-cell biology~7 days
TirzepatideGLP-1R + GIPRDual incretin pathways, adipose biology~5 days
CagrilintideAmylin receptorsCentral satiety signaling, combination models~7 days

Laboratory Handling Notes

GLP-1 class peptides are typically supplied as lyophilized powder. Reconstitute with bacteriostatic water using sterile technique. Store lyophilized stock at -20°C; reconstituted solutions at 2–8°C for up to 28 days. These peptides are sensitive to light and repeated freeze-thaw cycles. All Iron Labs GLP-1 peptides include COA documentation with HPLC and mass spec data.

Source GLP-1 research peptides from Iron Labs → Iron Labs Metabolic Peptide Catalog

Regulatory Notice

Semaglutide, Tirzepatide, and Cagrilintide are sold by Iron Labs exclusively as research chemicals for laboratory use. These compounds are not sold or intended for human therapeutic use. Iron Labs makes no health claims. Researchers are responsible for compliance with all applicable regulations in their jurisdiction.